在过去的二十年中,对Rab样蛋白1A(RBEL1A)的研究强调了该基因的致癌特性。尽管有新的证据,它在癌症生物学中的重要性被低估了。这是第一个RBEL1A关键审查涵盖其发现,生物化学,生理功能,和临床见解。适当水平的RBEL1A表达在正常细胞和组织中似乎是维持染色体稳定性所必需的;然而,它的过度表达与肿瘤发生有关。此外,将讨论RBEL1A信号通路的上游和下游靶标。机械上,RBEL1A通过增强Erk1/2、Akt、c-Myc,和CDK通路,同时通过抑制p53,Rb,和半胱天冬酶途径。更重要的是,这篇综述涵盖了RBEL1A在癌症领域的临床意义,如耐药和总体生存率差。此外,这篇综述指出了RBEL1A的瓶颈研究及其未来的研究方向。越来越清楚的是,RBEL1A可能作为抗癌治疗的有价值的靶标。遗传和药理学研究有望促进RBEL1A抑制剂作为癌症治疗药物的鉴定和发展。这无疑可以改善人类恶性肿瘤的管理。
Research on Rab-like protein 1A (RBEL1A) in the past two decades highlighted the oncogenic properties of this gene. Despite the emerging evidence, its importance in cancer biology was underrated. This is the first RBEL1A critical
review covering its discovery, biochemistry, physiological functions, and clinical insights. RBEL1A expression at the appropriate levels appears essential in normal cells and tissues to maintain chromosomal stability; however, its overexpression is linked to tumorigenesis. Furthermore, the upstream and downstream targets of the RBEL1A signaling pathways will be discussed. Mechanistically, RBEL1A promotes cell proliferation signals by enhancing the Erk1/2, Akt, c-Myc, and CDK pathways while blunting the apoptotic signals via inhibitions on p53, Rb, and caspase pathways. More importantly, this
review covers the clinical relevance of RBEL1A in the cancer field, such as drug resistance and poor overall survival rate. Also, this
review points out the bottle-necks of the RBEL1A research and its future research directions. It is becoming clear that RBEL1A could potentially serve as a valuable target of anticancer therapy. Genetic and pharmacological researches are expected to facilitate the identification and development of RBEL1A inhibitors as cancer therapeutics in the future, which could undoubtedly improve the management of human malignancy.